Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Sector: Medical
IDRA (NASDAQ: IDRA)
3m
6m
1y
2y
Ranking History
This Week
Last Week
Two Weeks Back
Three Weeks Back
Please login to view our current ranking data
Click here to login
No Information
No Information
No Information
Disclaimer
Headlines
Blog Articles
Press Releases
SEC
Idera Pharmaceuticals and Merck & Co., Inc. Extend Research Collaboration for Agonists of Toll-like Receptors as Vaccine Adjuvants
Nov 25, 2009 08:00 AM |
IDRA
,
MRK
Idera Pharmaceuticals Announces Termination of Asthma and Allergy Research Collaboration Agreement
Nov 25, 2009 07:30 AM |
IDRA
,
MRK
,
NVS
Idera Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides Pipeline Update
Nov 05, 2009 07:05 AM |
IDRA
Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
Nov 03, 2009 08:00 AM |
IDRA
Idera Pharmaceuticals Announces Issuance of Patents Covering its Novel Toll-like Receptor-Targeted Compounds and Their Use
Oct 26, 2009 08:00 AM |
IDRA
Idera Pharmaceuticals Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel(R) in Arthritis Model
Oct 19, 2009 09:00 AM |
IDRA
Idera Pharmaceuticals to Present at 8th Annual BIO Investor Forum
Oct 16, 2009 08:00 AM |
IDRA
Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection
Oct 07, 2009 08:00 AM |
IDRA
Idera Pharmaceuticals to Present at 11th Annual Massachusetts Biotechnology Investors Forum
Oct 01, 2009 08:00 AM |
IDRA
Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma
Sep 25, 2009 09:00 AM |
IDRA
More..
More..
Idera Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides Pipeline Update
Aug 04, 2009 07:12 AM |
IDRA
Idera Pharmaceuticals to Present at Upcoming Investor Conferences
Jul 31, 2009 08:01 AM |
IDRA
Idera Pharmaceuticals Provides Update on Drug Candidate Pipeline Targeted to Toll-like Receptors
Jun 16, 2009 10:03 AM |
IDRA
Idera Pharmaceuticals Announces Presentations of Preclinical Data on Modulation of Toll-like Receptors 3, 7, and 9 through Antisense
Jun 15, 2009 08:14 AM |
IDRA
Idera Pharmaceuticals to Present at Noble Financial Capital Market’s Fifth Annual Equity Conference
Jun 01, 2009 08:12 AM |
IDRA
Idera Pharmaceuticals to Present at BIO Business Forum and Participate in Panel at BIO 2009
May 15, 2009 08:06 AM |
IDRA
Idera Pharmaceuticals Announces Presentation of Preclinical Data on IMO-3100, a Lead TLR Antagonist Drug Candidate for Autoimmune Diseases, during American Association of Immunologists Annual Meeting
May 11, 2009 08:12 AM |
IDRA
Idera Pharmaceuticals Reports First Quarter 2009 Financial Results
May 06, 2009 07:17 AM |
IDRA
Idera Pharmaceuticals Announces Issuance of Patents Claiming Novel Toll-like Receptor-Targeted Immune Modulatory Oligonucleotides and Their Use
Apr 23, 2009 08:02 AM |
IDRA
Idera Pharmaceuticals to Present Preclinical Data on its Agonists of Toll-Like Receptors at AACR 2009 Annual Meeting
Apr 15, 2009 08:09 AM |
IDRA
More..
Form 4 IDERA PHARMACEUTICALS, For: Nov 24 Filed by: MUELLER HANS (10K)
Nov 24, 2009 06:18 PM
Form 4 IDERA PHARMACEUTICALS, For: Nov 12 Filed by: MUELLER HANS (10K)
Nov 12, 2009 06:42 PM
Form 4 MUELLER HANS For: Aug 04 (10K)
Aug 06, 2009 06:22 PM
Form 4 HARTLEY C KEITH For: Jun 16 (10K)
Jun 16, 2009 07:20 PM
Form 4 ZEIN YOUSSEF EL For: Jun 16 (10K)
Jun 16, 2009 06:56 PM
Form 4 ZEIN YOUSSEF EL For: May 29 (10K)
Jun 02, 2009 07:01 PM
Form 4 MUELLER HANS For: May 08 (10K)
May 11, 2009 12:46 PM
Form 4 ZEIN YOUSSEF EL For: Apr 24 (10K)
Apr 28, 2009 12:15 PM
Form 4 REARDON WILLIAM S For: Apr 01 (10K)
Apr 03, 2009 08:40 PM
Form 4 ZEIN YOUSSEF EL For: Mar 16 (10K)
Mar 18, 2009 02:08 PM
More..
Analyst Ratings
More Details
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
IDRA
Compare to S&P
YTD
-37.11 %
-47.95 %
4 Weeks
-30.40 %
-31.16 %
12 Weeks
-37.76 %
-41.32 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
-100.00 %
EPS Growth in Last Year:
-100.00 %
Sales Growth in Last Quarter:
-43.13 %
Sales Growth in Last Quarter:
-12.80 %
More...
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
